Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 5.

Koeberle, D; Dufour, J-F; Demeter, G; Li, Q; Ribi, K; Samaras, P; Saletti, P; Roth, A D; Horber, D; Buehlmann, M; Wagner, A D; Montemurro, M; Lakatos, G; Feilchenfeldt, J; Peck-Radosavljevic, M; Rauch, D; Tschanz, B; Bodoky, G; Swiss Group for Clinical Cancer Research (SAKK) (2016). Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). Annals of Oncology, 27(5):856-861.

Koeberle, D; Betticher, D C; von Moos, R; Dietrich, D; Brauchli, P; Baertschi, D; Matter, K; Winterhalder, R; Borner, M; Anchisi, S; Moosmann, P; Kollar, A; Saletti, P; Roth, A; Frueh, M; Kueng, M; Popescu, R A; Schacher, S; Hess, V; Herrmann, R (2015). Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Annals of Oncology, 26(4):709-714.

Zlobec, I; Molinari, F; Kovac, M; Bihl, M P; Altermatt, H J; Diebold, J; Frick, H; Germer, M; Horcic, M; Montani, M; Singer, G; Yurtsever, H; Zettl, A; Terracciano, L; Mazzucchelli, L; Saletti, P; Frattini, M; Heinimann, K; Lugli, A (2010). Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients. British Journal of Cancer, 102(1):151-161.

Bernhard, J; Dietrich, D; Scheithauer, W; Gerber, D; Bodoky, G; Ruhstaller, T; Glimelius, B; Bajetta, E; Schüller, J; Saletti, P; Bauer, J; Figer, A; Pestalozzi, B C; Köhne, C H; Mingrone, W; Stemmer, S M; Tàmas, K; Kornek, G V; Koeberle, D; Herrmann, R (2008). Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial - SAKK 44/00-CECOG/PAN.1.3.001. Journal of Clinical Oncology, 26(22):3695-3701.

Borner, M; Koeberle, D; Von Moos, R; Saletti, P; Rauch, D; Hess, V; Trojan, A; Helbling, D; Pestalozzi, B; Caspar, Christian; Ruhstaller, T; Roth, A; Kappeler, A; Dietrich, D; Lanz, D; Mingrone, W (2008). Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the swiss group for clinical cancer research SAKK. Annals of Oncology, 19(7):1288 -1292 .

This list was generated on Sun Sep 24 13:01:05 2017 CEST.